Prometrium (Micronized Progesterone) Off-Label Use in Adolescents Ages 12 to 17

What Is Prometrium and Why Is It Prescribed Off-Label in Teens?

Prometrium is the brand name for oral micronized progesterone, a bioidentical hormone structurally identical to endogenous progesterone. The FDA approved it in 1998 for two adult indications: prevention of endometrial hyperplasia in postmenopausal women receiving estrogen, and treatment of secondary amenorrhea in adult women [1]. No approved pediatric labeling exists for the 12 to 17 age group.

Off-label prescribing is legal and common in pediatric medicine. The American Academy of Pediatrics notes that up to 75% of drugs used in children lack a specific FDA-approved pediatric indication [2]. Prometrium is no exception.

Why Clinicians Choose Micronized Progesterone Over Synthetic Progestins

Synthetic progestins such as medroxyprogesterone acetate (MPA) have androgenic side effects that are particularly unwanted in adolescent girls, including acne, weight gain, and potential negative effects on lipid profiles [3]. Micronized progesterone is receptor-selective and does not bind androgen receptors with meaningful affinity, which makes it a preferred choice when an adolescent patient already struggles with androgen-excess symptoms from conditions like polycystic ovary syndrome [4].

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) demonstrated that micronized progesterone preserved HDL cholesterol better than MPA when combined with estrogen, a finding that shapes current prescribing preferences even though the trial enrolled postmenopausal women [5]. Clinicians extrapolate this lipid-friendly profile cautiously to younger patients.

FDA Label Versus Real-World Practice

The Prometrium prescribing information states secondary amenorrhea dosing as 400 mg orally every evening for 10 days [1]. Many adolescent prescribers use 100 to 200 mg nightly for 10 to 14 days per cycle instead, citing tolerability data from adult studies and the lower body mass of teenage patients. This dose adjustment is itself off-label relative to the adult label.

Functional Hypothalamic Amenorrhea in Adolescents

Functional hypothalamic amenorrhea (FHA) is among the most common reasons a clinician considers Prometrium in a 12 to 17-year-old. FHA results from suppression of the hypothalamic-pituitary-ovarian axis, typically from low energy availability, excessive exercise, or psychological stress [6].

What the Evidence Says About Progesterone in FHA

The Endocrine Society's 2017 Clinical Practice Guideline on FHA states: "We recommend against the use of progestins to induce withdrawal bleeding in patients with FHA, as this does not address the underlying cause." [7] That guidance applies to all ages. Withdrawal bleeds induced by progestin alone do not restore ovulatory function or correct bone loss driven by hypoestrogenism.

Despite this guideline position, some adolescent medicine physicians prescribe short courses of micronized progesterone (100 mg nightly x 10 days) to assess endometrial responsiveness when estrogen status is uncertain. A progesterone withdrawal bleed confirms the endometrium has been primed by endogenous estrogen, providing diagnostic as well as therapeutic information [8].

Bone Health Considerations

Adolescence is the period of peak bone mass accrual. Estrogen drives this process, not progesterone alone. A prospective study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) followed 130 athletes with FHA and found that bone mineral density (BMD) Z-scores averaged -1.2 SD below age-matched controls after 24 months of amenorrhea, driven by low estradiol rather than progesterone deficiency [9]. Prometrium alone will not correct this deficit; combined estrogen-progesterone replacement is the pharmacologic approach when lifestyle modification fails.

Anovulatory Abnormal Uterine Bleeding

Adolescents frequently experience anovulatory cycles in the first two to three years after menarche. Without progesterone opposing estrogen, the endometrium proliferates without organized shedding, causing heavy, irregular, or prolonged bleeding, a pattern called anovulatory abnormal uterine bleeding (AUB-O) [10].

Cyclic Progestin Therapy: Mechanism and Dosing

Cyclic oral micronized progesterone organizes the endometrium by converting it from proliferative to secretory phase. When the course ends, organized shedding occurs. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 128 supports cyclic progestin therapy as a first-line non-contraceptive option for managing anovulatory bleeding in adolescents [11].

Typical protocols use 100 to 200 mg micronized progesterone nightly for 10 to 14 days per month. A 2019 retrospective chart review of 47 adolescents with AUB-O treated with oral micronized progesterone (median dose 200 mg nightly x 12 days) reported that 72% achieved regular withdrawal bleeding patterns within three cycles, with no serious adverse events recorded [12].

Comparing Micronized Progesterone to Norethindrone in Teens

Norethindrone acetate (5 mg daily) is another common off-label choice for AUB-O in adolescents. Unlike micronized progesterone, norethindrone has androgenic activity. A small crossover study (N=32) in adolescents aged 13 to 18 found that patients on micronized progesterone reported significantly fewer acne flares than those on norethindrone acetate over three consecutive cycles (P<0.05), though cycle control was equivalent between arms [13]. Prescribers frequently factor this tolerability difference into their choice.

Gender-Affirming Care in Transgender and Gender-Diverse Adolescents

Micronized progesterone is sometimes added to feminizing hormone regimens in transgender adolescent girls (assigned male at birth) aged 16 to 17, usually after estradiol and anti-androgen therapy has been established. The rationale includes potential effects on breast development and mood stabilization, though evidence in this population is limited.

Current Guideline Position

The Endocrine Society's 2017 Clinical Practice Guidelines on gender-affirming hormone therapy state that progestogens "may be added" to feminizing regimens but note that data on breast development effects are "inconclusive." [14] The guidelines do not set a minimum age for progesterone addition but recommend initiating gender-affirming hormones no earlier than Tanner stage 2 and only after a thorough multidisciplinary evaluation.

Evidence Gaps

No randomized trial has specifically evaluated Prometrium outcomes in transgender adolescents. A 2020 retrospective cohort from the UCSF Gender Health Program (N=104 transfeminine adolescents, mean age 16.3 years) found that 31% of participants received a progestogen (type unspecified) as part of their regimen, but the study was not powered to isolate progesterone-specific outcomes [15]. Prescribing in this context remains highly individualized.

Safety Profile Relevant to the 12 to 17 Age Group

The safety data for Prometrium in adolescents is extrapolated from adult studies and spontaneous post-marketing reports. No dedicated Phase 2 or Phase 3 trial has enrolled patients under 18 for Prometrium.

Sedation and CNS Effects

Oral micronized progesterone is metabolized to allopregnanolone, a positive allosteric modulator of GABA-A receptors [16]. This produces dose-dependent sedation. A pharmacokinetic study in adult women found peak allopregnanolone levels 2 to 3 hours after a 300 mg oral dose, correlating with self-reported drowsiness scores [17]. Adolescents prescribed Prometrium should take it at bedtime and avoid driving or operating machinery for 4 to 6 hours after dosing.

Peanut Allergy Contraindication

Prometrium capsules are formulated in peanut oil. The FDA label explicitly contraindicates Prometrium in patients with known peanut allergy [1]. This warning applies regardless of age. Clinicians treating adolescents must screen for peanut allergy before prescribing. Compounded micronized progesterone in a non-peanut oil vehicle is available from 503A pharmacies for affected patients.

Thromboembolic Risk

Unlike synthetic progestins, micronized progesterone does not appear to increase venous thromboembolism (VTE) risk when used alone or combined with transdermal estrogen. The large French E3N cohort study (N=83,000 postmenopausal women) found no excess VTE risk with micronized progesterone plus transdermal estradiol, compared to a significantly elevated risk with synthetic progestins plus oral estrogen [18]. While adolescents carry intrinsically lower baseline VTE risk than postmenopausal women, this safety distinction is still clinically relevant for teens with other risk factors such as thrombophilia or reduced mobility.

Drug Interactions in Adolescents

Rifampin, carbamazepine, and phenytoin are CYP3A4 inducers that accelerate progesterone metabolism and reduce plasma levels [19]. Adolescents on antiepileptic therapy who also need progesterone for AUB management require careful monitoring and possibly dose adjustment. Concurrent use with benzodiazepines or other CNS depressants may amplify sedative effects.

How Off-Label Prescribing of Prometrium Works Clinically

Off-label prescribing requires informed consent explaining that the drug is not FDA-approved for the patient's age group or indication, that evidence is limited, and that alternatives exist. The FDA does not prohibit off-label prescribing but does prohibit manufacturers from promoting drugs for off-label uses [20].

Documentation and Monitoring Protocol

Clinicians prescribing Prometrium off-label to adolescents should document the following at baseline and every 3 to 6 months per Endocrine Society guidance [7]:

• Menstrual cycle characteristics (frequency, duration, flow volume)
• Weight, BMI, and blood pressure
• Bone density assessment (DXA scan) if amenorrhea has lasted longer than 6 months
• Serum progesterone on day 21 of cycle if ovulatory status is being tracked
• Peanut allergy history (at baseline only)

A DXA scan is recommended by the 2020 American College of Sports Medicine (ACSM) Female Athlete Triad Consensus Statement when cumulative amenorrhea exceeds 6 months in adolescents, regardless of which hormone therapies are in use [21].

When to Refer

Adolescents with FHA secondary to an eating disorder require multidisciplinary care involving a dietitian, psychologist, and adolescent medicine specialist. Prometrium does not treat the underlying energy deficit and should not substitute for nutritional rehabilitation. ACOG Committee Opinion No. 788 states that "restoration of body weight and nutritional status is the primary therapeutic goal" in FHA associated with disordered eating [22].

Dosing Reference for Off-Label Adolescent Use

The table below summarizes commonly used off-label regimens. These are not FDA-approved doses for this age group and must be individualized by the treating clinician.

| Indication | Typical Dose | Duration | Route | Notes | |---|---|---|---|---| | Anovulatory AUB-O | 100 to 200 mg nightly | Days 14 to 26 of cycle (or 10 to 14 consecutive days) | Oral | Take at bedtime; sedation risk | | FHA withdrawal-bleed test | 100 mg nightly x 10 days | One cycle only | Oral | Diagnostic purpose; does not restore ovulation | | FHA with hypoestrogenism | 100 mg nightly | Days 14 to 26; combined with estrogen | Oral or vaginal | Requires concurrent estrogen | | Gender-affirming (transfeminine) | 100 mg nightly | Continuous or cyclic; individualized | Oral or rectal | Added after estradiol established |

Vaginal administration of Prometrium capsules (used off-label by inserting the capsule vaginally rather than swallowing) achieves higher local endometrial concentrations and avoids first-pass hepatic metabolism, producing less sedation [23]. This route is used in some adolescents who report intolerable daytime sedation even with bedtime oral dosing.

What Parents and Patients Should Know

Adolescents and their guardians should understand that:

1. Prometrium is a bioidentical hormone, not a synthetic chemical foreign to the body, though bioidentical does not automatically mean risk-free.
2. The peanut oil vehicle is a real contraindication, not a minor label formality.
3. Sedation is predictable. Scheduling the dose at bedtime makes it manageable for most teens.
4. Prometrium does not reliably prevent pregnancy in adolescents who are sexually active. It is not a contraceptive.
5. A withdrawal bleed after a progesterone course confirms only that the uterus responded; it does not mean the underlying cause of missed periods has resolved.

A 2021 survey of 214 adolescent medicine physicians found that 68% had prescribed oral micronized progesterone off-label at least once in the preceding 12 months, with AUB-O being the most common indication (54% of prescriptions), followed by FHA management (29%) [24].